p53 is a tumor suppressor, which belongs to the p53 family of proteins. The family consists of p53, p63 and p73 proteins, which share similar structure and function.
Introduction
B-cell chronic lymphocytic leukaemia (CLL) is one of the most common forms of blood cancers 1, 2 . The incidence of CLL in the western world is 4.2/100 000 per year. In patients over the age of 80 years, the incidence increases to greater than 30/100 000 per year. CLL develops mostly in patients above the age of 72 years which is linked to poor prognosis 3 .
In Sweden, and worldwide, male show higher prevalence of lymphoid and haematological tissue cancers than women and the leukaemia incidence in both genders increases above the age of 55 4 .
Common chromosomal aberrations in CLL include deletions of 13q14, trisomy 12, 11q23 and 17p13 deletions or mutations 5 . Deletions of 17p13 and 11q23 affect p53 pathway and are linked with poor prognosis and faster disease progression 6 . Recent studies point to the positive outcome of the Bcl-2 inhibitor venetoclax in handling 17p-deleted relapsed/refractory CLL 7 . The clinical trial for the treatment-näive CLL elderly patients show promise for Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor 8 . However, the development of resistance to targeted therapies poses significant therapeutic constraints.
Introduction of new compounds into clinical practice is both, time constraining and a financial endeavour, which more often than not is subject to failure. Drug repurposing brings a selective advantage to the field of drug discovery as it is easier and more costeffective to authorize the approved drug for a new indication 9 .
Protoporphyrin IX (PpIX) is a natural precursor of heme and a metabolite of aminolevulinic acid, a photoactivable drug clinically used in photodynamic therapy and diagnosis 10 . In drug repurposing approach PpIX was identified as an activator of p53 and TAp73α tumor suppressors. Recent work demonstrates that PpIX inhibits TAp73/MDM2 and TAp73/MDM4 interactions, which leads to stabilisation of TAp73 protein and induction of TAp73-dependent apoptosis in cancers with TP53 gene mutations 11, 12 .
The tumor suppressor p53 is inactivated in the majority of tumors by mutations occurring in the TP53 gene 13 . In cancers retaining intact TP53 gene, p53 protein is targeted for degradation by the deregulated E3 ubiquitin ligase MDM2. In addition, MDM2 homolog, MDM4, protein binds p53 and inhibits its transcription activity 14 15 16 .
Activation of wild-type (wt) p53 is a promising therapeutic strategy, and the compounds inhibiting oncogenic MDM2 or modulating p53 post-translational modifications are currently in the clinical development 17 . However, due to systemic toxicity, highly selective inhibitors of p53/MDM2 interactions including analogues of nutlin, MI or RG compounds, have not been approved yet 18 19 . Even though the advancement in the field, these compounds cannot inhibit MDM4 protein and are thus inefficient in targeting tumors that overexpress MDM4 oncogene such as cutaneous melanomas 20 .
p73 is a tumor suppressor and induces apoptosis and tumor regression in a p53independent manner [21] [22] [23] . TP73 gene is rarely mutated in cancers and p73 protein is often inactivated by binding to oncogenic partners including MDM2, MDM4, ΔNp73 or mutant p53 24 . Strategies aiming at targeted activation of p73 in cancer are, however, at a very early stage of development.
Here, we applied a fluorescent two-hybrid assay and a yeast-based reporter assay and showed that PpIX inhibits p53/MDM2 and p53/MDM4 interactions. Next, analysis in cancer cells revealed that PpIX induces the p53-dependent apoptosis in B-CLL cells. We demonstrate that PpIX triggers accumulation of p53 and TAp73 and activates cell death at doses not affecting healthy peripheral blood mononuclear cells (PBMCs).
Materials and methods

Reagents and cell lines
Leukemic cells and PBMCs were cultured in RPMI-1640 (Roswell Park Memorial Institute) medium (Sigma-Aldrich, Munich, Germany) and HCT 116 cells in DMEM medium with 10% foetal calf serum (Sigma-Aldrich) and penicillin/streptomycin (10 units/ml) (Sigma-Aldrich) at 37 °C in a humidified 5% CO 2 /95% air atmosphere.
Cell Viability Assay
The viability of EHEB, HL60 and PBMCs after 72-hour treatment with PpIX was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay according to manufacturer's protocol. Briefly, 5mg/ml MTT solution was prepared in PBS buffer and filter-sterilized. Cells were washed once with RPMI-1640 medium and 1*10 5 cells/ml were transferred to eppendorf tubes and treated with 0.5%DMSO or the investigated compounds.
Next, cells were seeded onto 96 well plates at the density of 1*10 4 cells/well and incubated for 72h at 37 °C. After this time, MTT reagent was added to each well to a final concentration of 10% and the plates were incubated for 3h at 37 °C in a humidified 5% CO 2 /95% air atmosphere. The supernatant was removed and 200 μl DMSO/well was added.
The plates were incubated at 37°C for 30 min and the absorbance of the formazan was measured at 560 nm in a Perkin-Elmer (Waltham, MA, USA) microplate reader.
Untreated EHEB cells, RPMI 1640 medium and RPMI 1640 medium with 20μg/ml PpIX were used as background controls. The experiments were performed in triplicates and in at least three independent repeats.
Immunoprecipitation and western blot
Immunoprecipitation was performed using a modified protocol described previously 28 .
Briefly, HCT 116 cells were seeded in 10 cm dish at 4*10 6 cells, allowed to adhere overnight and treated with the compounds for 8h followed by 3h with 20 μM MG132. Cells were washed 2x with ice-cold PBS and solubilized in IP buffer: 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.5% Nonidet P-40 supplemented with protease inhibitors and lyzed on ice for 30 min and 1 mg of total protein in IP buffer was added to 30 μl mouse protein A agarose beads and 1 μg mouse anti-p53 DO-1 antibody or 1 μg normal mouse IgG and immunoprecipitated for 16h at 4°C. The beads were washed three times with buffer 1 (50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 500 mM NaCl, and 0.5% Nonidet P-40) and one time with buffer 2 (50 mM Tris-HCl pH 7.5, 5 mM EDTA, 150 mM NaCl). The beads were resuspended in 15 μl of lysis buffer and 5 μl of 5 × Laemmli buffer and boiled prior to western blot analysis.
For western blot, total proteins were transferred to HyBond membrane (GE healthcare), blocked with 5% milk in PBS for 20min and incubated with the relevant antibodies. After washing in PBS membranes were incubated with secondary antibodies (1:3000 in 5% milk) for 2h at room temperature. The protein signals were detected using Super Signal West Dura Extended Duration Substrate (Bio-Rad, Solna, Sweden) and ChemiDoc (Bio-Rad).
PBMCs were cultured in RPMI 1640 supplemented with 10% foetal calf serum and penicillin/streptomycin (10 units/ml) without supplementation with growth factors at 37 °C for three days before treatment with compounds.
Quantitative PCR
Quantitative PCR was performed as described previously 25, 29 . Briefly, cells were treated with 2.5 μg/ml PpIX for 8h. qPCR was performed using following primers pairs:
Gene
Forward Primer 5'-3' Reverse Primer 5'-3'
GAPDH TCATTTCCTGGTATGACAACG ATGTGGGCCATGAGGT
PUMA CTCAACGCACAGTACGAG GTCCCATGAGATTGTACAG
HMOX-1 TTCACCTTCCCCAACATTGC TATCACCCTCTGCCTGACTG
BAX GCTGTTGGGCTGGATCCAAG TCAGCCCATCTTCTTCCAGA
Fluorescence Activated Cell Sorting (FACS)
Cells were cultured in 6-well plates with 8*10 5 (K562 and HL60) and 1*10 6 PBMC cells and 2 ml media/well and treated with the compounds. Propidium iodide (PI) and FITC-Annexin V (both from BD Biosciences, CA, USA) staining was performed according to the manufacturer's protocols. For PBMCs, cells were washed and fixed with 500 μl ice-cold 70% ethanol and stored at 4°C. Next, cells were washed and stained in 300 μl PI solution, stained for 30 min, spanned down and suspended in 200 μl PBS. FACS was carried out using the CELLQuest software (CELLQuest, NJ, USA) as described previously 30 .
Yeast-based reporter assay
The yeast-based functional assay was conducted as previously described 31 . Briefly, the p53dependent yeast reporter strain yLFM-PUMA containing the luciferase cDNA cloned at the 
F2H®-analysis
The assay was developed and performed as described previously 34, 35 . Briefly, F2H®-analysis (ChromoTek GmbH, Planneg-Martinsried, Germany) was carried out to assess PpIX ability to disrupt p53/MDM2 and p53/MDM4 interactions in U2OS cells, when MDM2 or MDM4 was tethered in the nucleus. U2OS cells were co-transfected with LacI-GFP-MDM2 or MDM4 and RFP-p53 for 8h and then incubated with 1 or 10 μM of PpIX or nutlin for 16h.
Control interaction values in each independent experiment are normalized to 100%. Averaged interaction values for the treated cells were plotted for p53/MDM2 and p53/MDM4
interactions on the graph. Data is presented as mean ± s.e.m., n = 6, PpIX -p < 0.01, nutlin -
Results
PpIX ablates p53/MDM2 and p53/MDM4 interaction.
It has been previously shown that PpIX inhibits p53/MDM2 interactions, induces p53-dependent reporter and apoptosis in human cancer cells expressing wild-type p53 36, 37 .
Next, PpIX was described to inhibit TAp73/MDM2 and TAp73/MDM4 interactions and to activate the TAp73-dependent apoptosis in cancer cells harbouring mutant TP53 gene 29 12 .
The mechanism of inhibition of protein-protein interactions (PPIs) is via binding of PpIX to the N-terminus of TAp73 37 . Thus, here, we strived to investigate if PpIX, which unlike nutlin, binds to the N-terminus of p53 37 and not to MDM2, is also capable of inhibiting the interaction between p53 and MDM4. We engaged the Fluorescent Two-Hybrid (F2H ® ) analysis performed by ChromoTek GmbH in which the GFP-labelled MDM2 or MDM4 proteins (LacI-GFP-MDM2 or MDM4) were tethered at the nucleus of U2OS cells and examined for the localisation of the exogenously expressed RFP-labelled p53 protein before and after drug treatment for 16h. The data were analysed using fluorescent imaging as described previously 35 . We observed an inhibitory effect of 10 μM PpIX on both interactions -p53/MDM2 and p53/MDM4. Interaction values dropped from 100% in untreated cells down to 61 ± 8 % for p53/MDM2 (mean ± s.e.m, Student's t-test, p < 0.01, n = 6) and 79 ± 5 % for p53/MDM4 (p < 0.05, n = 6). For comparison, the reference compound, 10 μM nutlin-3, induced a similar reduction of the p53/MDM2 interaction (down to 60%), along with reductions of the p53/MDM2 interactions at a lower dose of 1 µM (p < 0.001, Student's ttest, n = 6). Nutlin-3 did not disrupt the p53/MDM4 interaction ( Figure 1A) .
Next, to determine that the inhibition of p53/MDM2 and p53/MDM4 complexes by PpIX is due to the direct interaction between the compound and p53 and not due to posttranslational modifications in the p53 protein, we employed a yeast-based reporter assay which allows measuring the transcription activity of human p53 using p53-dependent luciferase reporter 11, 31 To determine that PpIX inhibits p53/MDM4 interactions also in cancer cells, we treated HCT 116 human colon cancer cells with PpIX for 16h. To stabilize MDM4 that is otherwise driven to degradation by MDM2 released from the complex with p53 by PpIX, cells were treated with MG132. Immunoprecipitation with monoclonal anti-p53 DO-1 antibody was performed, and the membrane was blotted with the polyclonal anti-p53 FL-393.
The results demonstrate that PpIX readily inhibited the interaction between p53 and MDM4
( Figure 1C) . We detected unspecific binding of MDM4 to mouse IgG, however, the signal was much weaker than the one obtained for the untreated cells (Figure 1C) , thus the background binding does not affect the conclusion that PpIX readily inhibits p53/MDM4
interactions in cancer cells.
Thus, F2H® yeast-based reporter assay and pull down demonstrated that the binding of PpIX to p53 results in the inhibition of both p53/MDM2 and p53/MDM4
interactions.
PpIX inhibits proliferation and induces apoptosis in B-CLL leukaemia cells
PpIX was shown to induce apoptosis 39 The viability of EHEB and HL-60 cells was significantly reduced with the increasing concentrations of PpIX (Figure 2A, 2B) . Of note, PpIX did not inhibit the proliferation of PBMCs at the concentrations effective in cancer cells (Figure 2C) . Based on the above and the IC 50 values, which are 2.5 μg/ml for EHEB and 2.4 μg/ml for HL60, we next investigated the mechanism of growth inhibition of cancer cells by PpIX and applied 2.5 μg/ml dose in all further experiments.
To assess the induction of cancer cell death, cells were treated with PpIX and stained with propidium iodide (PI) or Annexin V. Compared with untreated control cells, PpIX-treated EHEB cells showed a significant increase in the PI positive population (late apoptosis), from 20.73% to 94.45% and in the Annexin V positive population (early apoptosis), from 21.74% to 39.59% (Figure 2D ) after 24h. After 48h treatment with PpIX, the increase in the PI positive population was from 22.98% to 94.94% and in the Annexin V positive population from 32.28% to 52.13% (Figure 2E) . We did not detect any increase of PBMCs in subG1 phase after treatment with 5 or 10 μg/ml PpIX, corroborating the lack of toxicity induction by PpIX in normal cells (Supplementary Figure 1A & B) . The results in PBMCs correlated with the lack of induction of growth inhibition when treated with PpIX as assessed by MTT assay suggesting a redundant role of PpIX in healthy PBMCs (Figure 2C) .
PpIX induces p53-and TAp73-dependent apoptosis in wt-p53 CLL cells but not in PBMCs
To determine the mechanism of induction of apoptosis by PpIX in CLL cells, EHEB cells were treated with 2.5 μg/ml PpIX for 8h and analysed for the expression of p53
and TAp73 apoptotic target genes BAX and PUMA by quantitative PCR (qPCR). Induction of BAX and PUMA on mRNA levels was detected ( Figure 3A) and this corresponded to the accumulation of BAX and PUMA protein levels as assessed by western blots (Figure 3B, C) .
As reported previously, consistently with the induction of BAX and PUMA, PpIX induced p53 and TAp73 levels in EHEB cells in a time-and dose-dependent manner (Figure 3B, C) .
Interestingly, p53 accumulated more rapidly comparing to TAp73, suggesting preferential binding of PpIX to p53 in EHEB cells (Figure 3C) . Induction of p53 preceded the accumulation of the apoptotic protein BID and cleaved PARP. In healthy PMBCs, 2.5 μg/ml PpIX induced p53 levels. However, it did not correlate with the induction of apoptotic p53 targets PUMA and BID (Figure 3D) . In cancer cells, in addition to PUMA and BAX, PpIX induced the expression of heme oxygenase HMOX-1 (Figure 3A) , a stress response gene. This is in agreement with the previous studies showing that PpIX induces antioxidant response in cancer cells 12 . PpIX is an inhibitor of thioredoxin reductase (TrxR), a selenoprotein that plays a critical role in the oxidoreductase system and is often overexpressed in cancers. Inhibition of TrxR by PpIX induces reactive oxygen species (ROS) in cancer cells, triggers antioxidant response and contributes to cancer cell death 12, 40 . Thus, we speculate that PpIX induces p53-and TAp73-dependent apoptosis and ROS in B-CLL cells without affecting non-transformed cells. The putative mechanism of leukaemia cells' death is via stabilisation of p53 and TAp73 resulting from the inhibition of their interactions with oncogenic MDM2 and MDM4, the parallel accumulation of ROS resulting from inhibition of TrxR and induction of potent apoptosis (Figure 3E) .
Discussion
Genetic or pharmacological restoration of wt-p53 activity leads to regression of tumors in vivo [41] [42] [43] . Several therapeutic strategies have been developed to activate the p53 protein in tumors depending on the TP53 gene status. Thus, in cancers, harbouring missense TP53 gene mutations, small molecules belonging to the group of Michael acceptors that target reactive cysteine groups in the p53 core domain were found to be highly effective. These compounds refold mutant p53 protein to wild-type like conformation and induce p53-dependent apoptosis both in cancer cells in vitro and in vivo [44] [45] [46] [47] . The most promising compound, a small molecule APR-246, a pro-drug converted to methylene quinuclidinone (MQ) is currently tested in Phase II trial in TP53-mutated high-grade serous ovarian cancer in combination with carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) (Clinical trial identifier: NCT02098343).
In cancers expressing wt-p53 protein, p53 pathway is often inhibited by the proteinprotein interactions. MDM2 protein is a major E3 ubiquitin ligase of p53, which binds to p53 in the absence of cellular stress. The binding is via the N-terminal transactivation domain of p53 and the central domain of MDM2, inhibits p53 transcription activity and drives p53 to ubiquitin-dependent degradation. In addition, MDM2 promotes its self-degradation as well as of its homolog, MDM4 protein. MDM4, unlike MDM2, does not degrade p53 but binds to p53 N-terminus and inhibits its transcription activity. MDM2 and MDM4 are often overexpressed in cancers and therefore serve as promising therapeutic targets 20, 43, 48 . A large data of evidence shows that small-molecule antagonists of MDM2 restore the activity of wt-p53 in cells and thus are promising candidates for improved therapy of wtTP53 cancers.
Several compounds that bind to MDM2 and inhibit p53/MDM2 interactions are in pre-clinical and clinical development [49] [50] [51] . However, the high-affinity inhibitors of MDM2 might not be applicable in the clinical practice due to the development of resistant mutations.
A recent study showed that prolonged exposure of wt-p53 harbouring cancer cells to RG7388 (idasanutlin) leads to the development of resistant mutations in the TP53 gene 52 . Several clinical studies with a small molecule MDM2 inhibitor, AMG-232, which binds with picomolar affinity to MDM2 53 are on-going; however, the compound is not approved yet and targets only MDM2 oncoprotein, without displaying inhibitory effect towards MDM4.
Studies have shown that PpIX, induces apoptosis in cancer cells, binds to p53 and
TAp73 and induces p53-downstream apoptotic genes 11, 36, 37 . Cancer cells harbouring wtTP53 gene, undergo cell death via a p53-dependent mechanism as PpIX inhibits p53/MDM2 complexes which leads to p53 stabilisation and a subsequent induction of apoptosis 36 55 .
Previous studies showed that PpIX induces apoptosis in human lung and pancreatic cancer cells by activating TAp73. However, the potency of the compound against haematological tissue cancers has not been tested. We applied B-CLL cell line EHEB, harbouring wtTP53 gene and showed the induction of apoptosis by PpIX at concentrations that have no effect on normal PBMCs. The p53-null HL60 cells were also sensitive at the tested doses; however, the induction of apoptosis has not been unequivocally studied. Next, late cardio-toxicities of anthracycline and anthraquinone frequently used in HSCT is often a significant health burden in childhood cancer survivors 63 . Thus, new treatment strategies are needed to treat paediatric leukaemia patients.
PM2, a stapled peptide that binds to MDM2 and MDM4 and stabilizes p53 has been recently described 64 and a small molecule, LEM2, inhibiting both TAp73/MDM2 and TAp73/MDM4 interactions has been discovered in a yeast-based reporter assay 65 However, in comparison to PpIX, the capacity of these compounds in activating both p53 and TAp73
have not been unequivocally tested.
The exact mechanism of how PpIX inhibits p53 and p73 interactions with MDM2 and MDM4 remains to be elucidated. We speculate that by binding to p53 or p73 Nterminus, PpIX might alter the conformation of the α-helix spanning the MDM2 binding residues F19, W23, and L26, which might in turn prevent the interaction between p53/MDM2 and p53/MDM4.
Summing up, our study demonstrates that PpIX is a potent activator of p53 and TAp73 in B-CLL. Our findings might speed up repurposing of PpIX in treating cancers containing wt-p53 and TAp73 and with high expression of MDM2 and MDM4 oncogenes.
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